Drug Profile
Research programme: glucagon-like peptide 1 receptor positive allosteric modulators - Domain Therapeutics
Alternative Names: GLP-1R PAMsLatest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Domain Therapeutics
- Class Small molecules
- Mechanism of Action Glucagon-like peptide 1 receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Type 2 diabetes mellitus
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Type-2-diabetes-mellitus in France
- 20 Nov 2009 Domain Therapeutics' programme of glucagon-like peptide 1 receptor positive allosteric modulators is available for partnering (http://www.domaintherapeutics.com)